Clinical trials: Subjects With Type 2 Diabetes Mellitus.
Type 2 Diabetes Mellitus
Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes
The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02715258
- Testing
- Bexagliflozin
- Where
- 23 sites in United States, Canada
- Volunteers
- 210 people
- Sponsor
- Theracos
Diabetes Mellitus, Type 2, Overweight
Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects
This trial is conducted in china. The aim of the trial is as follows: To assess the effect of multiple subcutaneous injections of JY09 injection on the pharmacokinetic (PK) profile of multiple oral doses of metformin…
- Trial name
- NCT06247748
- Testing
- Exendin-4 Fc fusion protein (JY09) injection, Metformin Hydrochloride tablet, Rosuvastatin calcium tablets
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Beijing Dongfang Biotech Co., Ltd.
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)
This is an active- and placebo-controlled, single-site, four-part trial of MK-1092 in healthy adult participants, in participants with type 1 diabetes mellitus (T1DM), and in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03170544
- Testing
- MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type II Diabetes
Mass Balance and Biotransformation of [14C]HSK7653 in Human
A single-center, single-dose, non-randomized, open-label design.
- Trial name
- NCT04540016
- Testing
- [14C]HSK7653
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
Diabetes Mellitus, Non-Insulin-Dependent
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus
This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes.
- Trial name
- NCT00035984
- Testing
- AC2993
- Where
- 100 sites in United States
- Volunteers
- 734 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.
The purpose of this study is to assess the pharmacokinetics and safety of a single subcutaneously injected dose of albiglutide in subjects with type 2 diabetes mellitus with varying degrees of renal function, including subjects…
- Trial name
- NCT00938158
- Testing
- albiglutide
- Where
- 7 sites in United States, South Africa
- Volunteers
- 75 people
- Sponsor
- GlaxoSmithKline
Epicardial Fat
Semaglutide vs Dulaglutide on Epicardial Adipose Tissue
Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R).
- Trial name
- NCT04200625
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Miami
Type 2 Diabetes
Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
This is a non-inferiority study comparing omarigliptin with sitagliptin in participants with type 2 diabetes mellitus (T2DM) with inadequate glycemic control on metformin therapy.
- Trial name
- NCT01841697
- Testing
- Omarigliptin, Sitagliptin, Open-label Metformin
- Volunteers
- 642 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects
This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (exposure of drug) and pharmacodynamics (effect of drug) of NNC 0148-0000-0362 as tablets in healthy…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01597713
- Testing
- NNC 0148-0000-0362, insulin glargine
- Where
- Germany
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes
A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas
The purpose of this trial is to understand if adding saxagliptin to a sulfonylurea is safe and works better than increasing the amount of sulfonylurea a patient takes
- Trial name
- NCT00313313
- Testing
- Saxagliptin, Glyburide, Metformin
- Where
- 115 sites in United States, Argentina and 11 more
- Volunteers
- 768 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Expression of G-protein Coupled Receptor 120 Receptor in Adipose Tissue of German Diabetes Center Cohort Subjects
G-protein coupled receptor 120 (GPR120) is a G-protein-coupled receptor whose endogenous ligands have been identified as long-chain fatty acids.
- Trial name
- GPR120 (NCT03285750)
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- German Diabetes Center
Diabetes Mellitus, Type 2
A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.
The study is being conducted to evaluate the efficacy and safety of Noiiglutide Injection as mono-therapy with different doses in subjects with type 2 diabetes compared to placebo for 16 weeks.
- Trial name
- NCT03848793
- Testing
- HS-20004
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type2 Diabetes Mellitus
Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus
This crossover study investigates the safety, tolerability, pharmacokinetics (PK) ,pharmacodynamics (PD) effect of three dose levels of PB-201,and characterizes the PK profile of a prominent des-methyl metabolite of…
- Trial name
- NCT03973515
- Testing
- glucokinase activator
- Where
- China
- Volunteers
- 16 people
- Sponsor
- PegBio Co., Ltd.
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Taiwan
This study is conducted in Asia. The aim of this observational study is to evaluate the current status of diabetes management, control, and complications in diabetic subjects in Asia.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DiabCare Asia (NCT00887874)
- Testing
- No treatment given
- Where
- Taiwan
- Volunteers
- 2,370 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, CV Risk
Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects
The primary objective of this study is to assess the total CV risk in patients with type 2 diabetes and also to assess the impact of rosiglitazone in the total CV risk and the parameters of metabolic syndrome.
- Trial name
- NCT00648284
- Volunteers
- 1,100 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
Metabolic Effects of Gastrointestinal Surgery in T2DM
Gastric bypass surgery resolves type 2 diabetes mellitus (T2DM) without the need for diabetes therapy in ~80% of patients. Moreover, improvement in insulin sensitivity and glucose homeostasis occurs within days after surgery…
- Trial name
- NCT01771185
- Testing
- Duodenal jejunal bypass plus sleeve gastrectomy, Best medical treatment (Metformin ; gliclazide)
- Volunteers
- 24 people
- Sponsor
- University of Sao Paulo
Diabetes Mellitus
Preventing Renal Functional Abnormalities With Calorie Restriction in Subjects With Abdominal Obesity and Type 2 Diabetes at Increased Renal and Cardiovascular Risk
The study investigates whether a caloric restricted dietary regime can prevent onset and/or progression of chronic kidney disease in type 2 diabetic patients with abdominal obesity, through the amelioration of concomitant…
- Trial name
- CRESO (NCT01213212)
- Testing
- Caloric restriction, No intervention
- Where
- Italy
- Volunteers
- 73 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Diabetes, Diabetes Mellitus, Type 2
Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to evaluate the incidence of serious adverse drug reactions when initiating insulin therapy with NovoMix® 30 in subjects with type 2 diabetes mellitus under normal…
- Trial name
- Start (NCT01486875)
- Testing
- biphasic insulin aspart 30
- Where
- Sweden
- Volunteers
- 1,155 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State
The purpose of this study is to demonstrate bioequivalence of coadministered drugs on healthy subjects.
- Trial name
- NCT02223065
- Testing
- Saxagliptin, Dapagliflozin
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Trial Investigating the Dose Linearity and Safety of BC Combo THDB0207 in Subjects With Type 2 Diabetes
This is a randomised, double-blind, four-period crossover euglycaemic clamp trial in subjects with type 2 diabetes. Each subject will be randomly allocated to one of four treatment sequences.
- Trial name
- NCT05373212
- Testing
- Euglycemic clamp with BC Combo THDB0207, Euglycemic clamp with Humalog® Mix25
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Adocia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.